Lv1
40 积分 2025-10-10 加入
Risankizumab for Ulcerative Colitis
2天前
已完结
Pharmacokinetics, Safety, and Tolerability of GS‐1427, an Oral Prodrug of a Potent and Selective α4β7 Integrin Inhibitor, in Healthy Participants
24天前
已完结
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
1个月前
已完结
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX
1个月前
已完结
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
1个月前
已完结
Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial
1个月前
已关闭
Upadacitinib Maintenance Therapy in Crohn’s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study
1个月前
已完结
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies
1个月前
已完结
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
1个月前
已完结
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
1个月前
已完结
皖公网安备34019202002308
